ARDX

Ardelyx, Inc. NGM · ARDX

$5.08 -0.01 (-0.20%)

Pullback · -1.08σ

+ Compare Open in Sniper

Mkt cap $1.3B

P/E —

Day $5.00 – $5.09

52wk $4.93 – $8.40

Avg vol 4.0M

Beta 0.60

Div yld —

Next earnings 2026-04-30

Quick read

At a glance

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

ARDX last traded at $5.08, down 0.2% on the day; that's in the lower part of its 52-week range ($4.93–$8.4). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

The next scheduled earnings report (2026-04-30) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — not meaningfully overheated yet.

Long —

Setup score 14 / 100

Price is stretched slightly below its normal range — a light stretch — early days, worth watching.

· KC1 lower stretch — light dip
· Counter-trend long in strong downtrend

Technical read: KC1 lower, -0.96 ATR from EMA21 · no notable pattern

What it means: Price is stretched slightly below its normal range — a light stretch — early days, worth watching. The trigger bar shows no standout candle signal yet.

Score split: chart signals 14 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 14 pts

Cycle position 14

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 19 / 100

Price is sitting close to its normal range — not meaningfully overheated yet.

· Stochastic bear cross
· Aligned with strong downtrend (strong tailwind)

Technical read: below KC1 upper, -0.96 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 19 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 19 pts

Cycle position 6

Momentum 3

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $0.04 (fair range $0–$5); today's price sits 14155% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Overvalued -14155% margin of safety Accounting: Weak

Intrinsic (DCF)

$0.04

Fair-value range

$0.01 – $4.95

Margin of safety

-14155%

Accounting quality Weak

✓ More cash than debt
✓ Quick ratio 3.50 (antifragile)
✓ Current ratio 4.31 (antifragile)
✓ Gross margin 75% (pricing power)

⚠ Debt/equity 2.00 (fragile)
⚠ Negative retained earnings
⚠ Stock comp 12% of revenue (heavy dilution)

Key statistics

All statistics →

ARDX is a $1.3 billion company, it moves more calmly than the market (beta 0.6), and the stock is trading near the bottom of its 52-week range.

Market cap $1.3B

P/E ttm —

Beta 0.60

52w range $4.93 – $8.40

Avg volume 4.0M

Dividend yield —

Sector Healthcare

Next earnings 2026-04-30

52-week range · today's price

$4.93$8.40

More on ARDX

Options idea

See more →

CALL $5 2026-08-21

$0.45

PUT $6 2026-08-21

$1.10

Earnings

See more →

Last reported: 2026-04-30
EPS (act / est): -0.15 / -0.14
Surprise: -5.0%
Next report: 2024-10-31

About

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chroni…